TY - JOUR
T1 - Positivity and Follow-up Testing of Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Universally Screened Female Basic Military Trainees
AU - Townsend, Lisa C
AU - Stahlman, Shauna L
AU - Escobar, James D
AU - Osuna, Angela B
AU - Casey, Theresa M
AU - Winkler, Erin L
AU - Kieffer, John W
AU - Okulicz, Jason F
AU - Yun, Heather C
AU - Marcus, Joseph E
N1 - Publisher Copyright:
Copyright © 2024 by the American Sexually Transmitted Diseases Association.
PY - 2024
Y1 - 2024
N2 - Introduction Follow-up testing is recommended three months after patients initially test positive with Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). Follow-up testing adherence in the United States has been reported below one third of women, even in universally insured populations. We assessed both the positivity of CT and GC infections in female basic military trainees and the rates of follow-up testing for those who tested positive. Methods Between January 1, 2006-December 31, 2021, female Air Force Basic Military Trainees were universally screened with urinary nucleic acid amplification testing for CT and GC. Those who tested positive were evaluated to determine demographic information as well as follow-up testing rates. Patients who were evaluated with a repeat CT/GC NAAT test within 12 months after a positive CT/GC test result were considered to have received appropriate follow-up. Results 5,022 (5.2%) of 97,168 trainees tested positive for only-CT (4,749 (4.8%)), only GC (138 (0.1%)) or both CT/GC (135 (0.1%) during the study period. Those at increased risk of infection were those <24 years of age, Hispanic and Black individuals, high school education level, and single women. Of the 4,687 still in the military at three months after diagnosis, 3,268 (69.7%) had repeat testing within 12 months. There was no significant difference in follow-up testing by age, race, educational level, marital status, or organism causing original infection. Conclusion Follow-up testing among female USAF basic military trainees is higher than in other universally insured populations. This study demonstrates remaining barriers to adherence to recommended guidelines.
AB - Introduction Follow-up testing is recommended three months after patients initially test positive with Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). Follow-up testing adherence in the United States has been reported below one third of women, even in universally insured populations. We assessed both the positivity of CT and GC infections in female basic military trainees and the rates of follow-up testing for those who tested positive. Methods Between January 1, 2006-December 31, 2021, female Air Force Basic Military Trainees were universally screened with urinary nucleic acid amplification testing for CT and GC. Those who tested positive were evaluated to determine demographic information as well as follow-up testing rates. Patients who were evaluated with a repeat CT/GC NAAT test within 12 months after a positive CT/GC test result were considered to have received appropriate follow-up. Results 5,022 (5.2%) of 97,168 trainees tested positive for only-CT (4,749 (4.8%)), only GC (138 (0.1%)) or both CT/GC (135 (0.1%) during the study period. Those at increased risk of infection were those <24 years of age, Hispanic and Black individuals, high school education level, and single women. Of the 4,687 still in the military at three months after diagnosis, 3,268 (69.7%) had repeat testing within 12 months. There was no significant difference in follow-up testing by age, race, educational level, marital status, or organism causing original infection. Conclusion Follow-up testing among female USAF basic military trainees is higher than in other universally insured populations. This study demonstrates remaining barriers to adherence to recommended guidelines.
KW - Chlamydia trachomatis
KW - Follow-up Testing
KW - Neisseria gonorrhoeae
KW - Universal Screening
UR - http://www.scopus.com/inward/record.url?scp=85210083183&partnerID=8YFLogxK
U2 - 10.1097/OLQ.0000000000002099
DO - 10.1097/OLQ.0000000000002099
M3 - Article
C2 - 39508481
SN - 0148-5717
JO - Sexually transmitted diseases
JF - Sexually transmitted diseases
M1 - 10.1097/OLQ.0000000000002099
ER -